Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Hannouf, Malek B ^a   Sehgal, Chander ^b   Cao, Jeffrey Q ^b,c   Mocanu, Joseph D ^b   Winquist, Eric ^a   Zaric, Gregory S ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETUXIMAB; CISPLATIN; CLINDAMYCIN; FLUOROURACIL; HYDROCORTISONE; MINOCYCLINE;

ANAPHYLAXIS; ANOREXIA; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; DYSPNEA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE SYSTEM; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEPSIS; SKIN MANIFESTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, THEORETICAL; PLATINUM;

EID: 84862680911     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038557     Document Type: Article

References (51)

1. Canadian Cancer Society, National Cancer Institute of Canada (2009) Canadian Cancer Statistics, Toronto, Canada.
2. Colevas AD, (2006) Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2644-2652.
3. Stenson KM, Brockstein BE, (2011) Overview of head and neck cancer. In: UpToDate. Available:www.uptodate.com/contents/overview-of-head-and-neck-cancer?source=search_result&search=headandneckcancer&selectedTitle=~1150. Accessed 2011 Feb 20.
4. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J, (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318.
5. Bernier J, (2008) Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol 5: 705-713.
6. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, et al. (2007) Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98: 1275-1280.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
8. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
9. Ho C, (2010) Cetuximab in locally advanced head-and-neck cancer: defining the population. Curr Oncol 17: 48-51.
10. National Institute for Health and Clinical Excellence (NICE) (2008) Cetuximab for the Treatment of Locally Advanced Squamous Cell Cancer of the Head and Neck. NICE Technology Appraisal Guidance 145. London, U.K.
11. National Institute of Health and Clinical Excellence (NICE) (2010) Guidance on cetuximab for the treatment of recurrent or metastatic head and neck cancer (squamous cell carcinoma). Available:www.nice.org.uk/nicemedia/live/12179/44644/44644.pdf. Accessed 2010 Jun 15.
12. Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J, (2010) Prognostic factors in cancer of unknown primary site. Tumori 96: 111-116.
13. Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW, (1977) CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61: 359-366.
14. Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, et al. (2009) Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 101: 1182-1192.
15. Cancer Care Ontario-Drug Formulary, (2011) Accessed 2011 Mar 22. Available:www.cancercare.on.ca.
16. Sonnenberg FA, Beck JR, (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13: 322-338.
17. Statistics Canada/Health Statistics Division (2006) Life Tables, Canada and the Provinces, 2000-2002. Ottawa, Ontario, Canada, Minister of Industry, publication 84-537-XIE.
18. Patented Medicine Prices Review Board, (2009) Report on New Patented Drugs-Erbitux. Available:www.pmprb-cepmb.gc.ca/english/View.asp?x=669&mp=572 Accessed 2011 Apr 27.
19. Hoch J, (2012) Cost of cetuximab. Cancer Care Ontario; Personal Communication.
20. London Health Sciences Centre: London Regional Cancer Program (LRCP) (2011) Formulary. Toronto, ON, Canada.
21. Ontario Ministry of Health and Long-Term Care (2011) Ontario Case Costing Initiative (OCCI). Available:www.mohltcim.com/occp/occpreports/. Accessed 2011 Apr 28.
22. Ferte C, Penel N, Bonneterre J, Adenis A, (2010) Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary. Oncology 78: 87-93.
23. National institute of health and Clinical Excellence (NICE) (2009) Manufacturer's submission: cetuximab for the treatment of recurrent or metastatic head and neck cancer (squamous cell carcinoma). Available:www.nice.org.uk/guidance/index.jsp?action=article&o=42913#three. Accessed 2010 Jun 15.
24. Brown B, Diamantopoulos A, Bernier J, Schoffski P, Hieke K, et al. (2008) An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 11: 791-799.
25. Pohjolainen V, Rasanen P, Roine RP, Sintonen H, Wahlbeck K, et al. (2010) Cost-utility of treatment of bulimia nervosa. Int J Eat Disord 43: 596-602.
26. Vold Pepper P, Owens DK, (2000) Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin Infect Dis 30: 157-164.
27. Grutters JP, Joore MA, Wiegman EM, Langendijk JA, de Ruysscher D, et al. (2010) Health-related quality of life in patients surviving non-small cell lung cancer. Thorax 65: 903-907.
28. Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, et al. (2008) The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36: 1168-1174.
29. Mavranezouli I, (2010) A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics 28: 1109-1121.
30. Avritscher EB, Shih YC, Sun CC, Gralla RJ, Grunberg SM, et al. (2010) Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol 8: 242-251.
31. Fryback DG, Lawrence WF Jr, (1997) Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making 17: 276-284.
32. Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the economic evaluation of health technologies [3rd Edition]. Ottawa, Canada.
33. McKenna C, Claxton K, (2011) Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis. Med Decis Making 31: 853-865.
34. Laupacis A, Feeny D, Detsky AS, Tugwell PX, (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146: 473-481.
35. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J, (2007) Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23: 36-42.
36. McCabe C, Tsuchiya A, Claxton K, Raftery J, (2007) Assessing the economic challenges posed by orphan drugs: a comment on Drummond, et al. Int J Technol Assess Health Care 23: 397-401; author reply 401-394.
37. Simoens S, Dooms M, (2011) How much is the life of a cancer patient worth? A pharmaco-economic perspective. J Clin Pharm Ther 36: 249-256.
38. Hughes DA, Tunnage B, Yeo ST, (2005) Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 98: 829-836.
39. Sambrook J, Levy AR, Johnston KM, Ricard NJ, Bourgault C, et al. (2009) Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada. J. Clin. Oncol. 27(15), e17000.
40. Drummond MF, Mason AR, (2007) European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 25: 191-195.
41. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, (2010) Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 17: 37-48.
42. BC Cancer Agency (2010) bcca Protocol Summary for Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Vancouver: BC Cancer Agency. Available:www. bccancer.bc.ca/NR/rdonlyres/B6382FB0-629C-4F1C-9F3D- 24E0D09C456A/44569/UHNLACETRT_Protocol_1Apr2010.pdf. Accessed 2010 Jun 11.
43. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28.
44. Cancer care Ontario, (2004) Program in evidence based care. The Role of Trastuzumab (Herceptin?) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer Practice Guideline Report #1-15 (Version 2.2004). Available:www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13870 Accessed 2010 June 15.
45. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, et al. (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 25: 18s (suppl; abstr 4000).
46. National institute of health and Clinical Excellence (NICE) (2009) Guidance on cetuximab in treatment of metastatic colorectal cancer. Available:www.nice.org.uk/nicemedia/pdf/TA176Guidance.pdf Accessed 2010 Jun 15.
47. Anderson JA, Irish JC, Ngan BY, (1992) Prevalence of RAS oncogene mutation in head and neck carcinomas. J Otolaryngol 21: 321-326.
48. Rathcke IO, Gottschlich S, Gorogh T, Lippert BM, Werner JA, (1996) [Incidence of point mutations in Ki-ras codon 12 and 13 in squamous epithelial carcinomas of the head-neck region]. Laryngorhinootologie 75: 465-470.
49. Ontario Ministry of Health and Long-Term Care (2007) Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. Available:www.health.gov.on.ca/english/providers/program/ohip/sob/sob_mn.html. Accessed 2010 Jun 20.
50. Mittmann N, Verma S, Koo M, Alloul K, Trudeau M, (2010) Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer. Curr Oncol 17: 7-16.
51. Bank of Canada, (2011) Home & Rates and Statistics & Related Information & Inflation Calculator. Ottawa, ON: Bank of Canada; n.d. Available:www.bankofcanada.ca/en/rates/inflation_calc.html. Accessed 2011 Apr 27.